A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

Trial Profile

A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Ataluren (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Mar 2016 According to a PTC Therapeutics media release, the company intends to submit results of a recently completed Phase 3 study (CTP 237860) for review by Health Canada as part of the New Drug Submission (NDS) for Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy (nmDMD). In order to submit this additional data for review, the company will withdraw current NDS and resubmit the NDS with phase 3 results. As a result, the company no longer expects review of the NDS in 1H 2016.
    • 18 Sep 2015 Health Canada has initiated their review of the company's New Drug Submission for Translarna (ataluren) to treat nonsense mutation dystrophinopathy. The NDS will be reviewed with advance consideration under the Health Canada policy of Notice of Compliance with Conditions (NOC/c), according to a PTC Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top